The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer
Open Access
- 25 November 2014
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (2) , 1090-1100
Abstract
Cervical cancer is the third most common cancer in women worldwide. In the present study, global microRNA profiling for 79 cervical cancer patient samples led to the identification of miR-218 down-regulation in cervical cancer tissues compared to normal cervical tissues. Lower miR-218 expression was associated significantly with worse overall survival (OS), disease-free survival (DFS), and pelvic/aortic lymph node recurrence. In vitro, miR-218 over-expression decreased clonogenicity, migration, and invasion. Survivin (BIRC5) was subsequently identified as an important cervical cancer target of miR-218 using in silico prediction, mRNA profiling, and quantitative real-time PCR (qRT-PCR). Concordant with miR-218 over-expression, survivin knockdown by siRNA decreased clonogenicity, migration, and invasion. YM155, a small molecule survivin inhibitor, significantly suppressed tumor growth and lymph node metastasis in vivo. Our findings demonstrate that the miR-218~survivin axis inhibits cervical cancer progression by regulating clonogenicity, migration, and invasion, and suggest that the inhibition of survivin could be a potential therapeutic strategy to improve outcome in this disease.Keywords
This publication has 32 references indexed in Scilit:
- Unravelling the complexity of metastasis — molecular understanding and targeted therapiesNature Reviews Cancer, 2011
- miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 PathwayCancer Research, 2011
- A MicroRNA Expression Signature for Cervical Cancer PrognosisCancer Research, 2010
- Patterns of Known and Novel Small RNAs in Human Cervical CancerCancer Research, 2007
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006
- MicroRNAsCell, 2004
- Cervical cancerThe Lancet, 2003
- Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysisThe Lancet, 2001
- Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical CarcinomaNew England Journal of Medicine, 1999
- Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical CancerNew England Journal of Medicine, 1999